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X chromosome inactivation (XCI) depends on the
long noncoding RNA Xist and its recruitment of Poly-
comb Repressive Complex 2 (PRC2). PRC2 is also
targeted to other sites throughout the genome to
effect transcriptional repression. Using XCI as a
model, we apply an unbiased proteomics approach
to isolate Xist and PRC2 regulators and identified
ATRX. ATRX unexpectedly functions as a high-affin-
ity RNA-binding protein that directly interacts with
RepA/Xist RNA to promote loading of PRC2 in vivo.
Without ATRX, PRC2 cannot load onto Xist RNA
nor spread in cis along the X chromosome. More-
over, epigenomic profiling reveals that genome-
wide targeting of PRC2 depends on ATRX, as loss
of ATRX leads to spatial redistribution of PRC2 and
derepression of Polycomb responsive genes. Thus,
ATRX is a required specificity determinant for PRC2
targeting and function.INTRODUCTION
In mammals, X chromosome inactivation (XCI) balances X chro-
mosome gene dosages between the two sexes. During random
XCI in the peri-implantation embryo, cells count X chromosomes
and stochastically choose one X chromosome for inactivation
(Dupont and Gribnau, 2013; Lee, 2012; Lee and Bartolomei,
2013; Starmer and Magnuson, 2009; Wutz, 2011). Once
silenced, the inactive X chromosome (Xi) is maintained in a
repressed state through subsequent cell divisions. XCI is
controlled in cis by the ‘‘X inactivation center’’ (Xic), an X-linked
region that harbors many noncoding genes, including the
sense-antisense pair, Xist and Tsix (Brown et al., 1992; Lee
et al., 1999), and the activator, Jpx (Sun et al., 2013; Tian et al.,
2010). The 17 kb Xist RNA is transcribed exclusively from the
Xi and initiates silencing as it spreads over the X chromosome
in cis (Clemson et al., 1996). Xist is regulated negatively by the
antisense Tsix RNA (Lee et al., 1999) and positively by JpxRNA (Sun et al., 2013; Tian et al., 2010). Xist is also positively
controlled by the 1.6 kb internal transcript, RepA, which shares
the highly structured ‘‘Repeat A’’ motif with Xist RNA (Hoki
et al., 2009; Maenner et al., 2010; Zhao et al., 2008). The
outward spread of Xist RNA through the Xi leads to recruitment
of silencing factors that, in turn, establish and maintain the
repressed state (Dupont andGribnau, 2013; Lee and Bartolomei,
2013).
A key recruited factor is Polycomb repressive complex 2
(PRC2) (Dupont and Gribnau, 2013; Lee, 2012; Lee and Bartolo-
mei, 2013; Starmer and Magnuson, 2009; Wutz, 2011), the his-
tone methyltransferase complex that trimethylates histone H3
at lysine 27 (H3K27me3) and establishes repressive chromatin
(Mu¨ller and Verrijzer, 2009; Simon and Kingston, 2013).
Because PRC2 controls both normal development and the
pathogenesis of disease, PRC2 has become a high-priority
drug target (Helin and Dhanak, 2013). Apart from the Xi, PRC2
binds thousands of specific sites in the mammalian genome. Still
not fully understood is how PRC2 is targeted when the core sub-
units are not sequence-specific DNA-binding proteins. PRC2
preferentially occupies CpG-rich regions and is aided in recruit-
ment by substoichiometric association with the Jumonji protein,
JARID2, and the Zinc-finger protein, AEPB2 (Cifuentes-Rojas
et al., 2014; da Rocha et al., 2014; Kaneko et al., 2014; Simon
and Kingston, 2013). However, other specificity determinants
must exist in vivo, given that JARID2 and AEPB2 are nonspecific
DNA-binding proteins and cannot by themselves impart speci-
ficity to PRC2 localization.
The example of RepA/Xist RNA demonstrates that cis-regula-
tory RNAs can serve as locus-specific recruiting factors (Zhao
et al., 2008). Because such transcripts are unique in the genome,
their cis-action enables targeting of chromatin complexes to a
singular location (Lee, 2012). During XCI, PRC2 is first targeted
to the Xic by RepA via the Repeat A motif. Xist RNA then cotran-
scriptionally binds PRC2 via Repeat A and loads in cis onto a
nucleation center before spreading outwardly to envelop the Xi
(Jeon and Lee, 2011). PRC2 is now known to have a large RNA
interactome, with membership exceeding 9,000 transcripts (Ka-
neko et al., 2013; Kanhere et al., 2010; Khalil et al., 2009; Zhao
et al., 2010). In vitro, PRC2 can bind RNAwith a range of affinities
(Cifuentes-Rojas et al., 2014; Davidovich et al., 2013). The largeCell 159, 869–883, November 6, 2014 ª2014 Elsevier Inc. 869
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Figure 1. A Proteomics Screen Identifies ATRX as a Candidate XCI Regulator
(A) IP-MS: Colloidal blue staining of FLAG IP from control (293F) and FLAG-mH2A-expressing 293 run on a 4%–20% (left) and a 6% (right) SDS gradient gel. FLAG
IP was validated by western blot.
(B) Left: Immunostaining of ATRX, EZH2, and H3K27me3 in WT and two independent stable ATRX-KD MEF lines (shATRX-1,-2). Sample size (n) and %EZH2
association with Xi are shown.
(legend continued on next page)
870 Cell 159, 869–883, November 6, 2014 ª2014 Elsevier Inc.
RNA interactome raises the question of how PRC2 discriminates
between RNA species in the physiological context. Here, we
investigate this question by carrying out an unbiased screen
for novel specificity determinants. We identify the chromatin re-
modeler, ATRX.
RESULTS
AProteomics Screen Identifies ATRX as aCandidate XCI
Regulator
Because the macroH2A (mH2A) histone variant is enriched
within gene-dense bands of the Xi together with Xist RNA and
PRC2 (Chadwick and Willard, 2004; Costanzi and Pehrson,
1998), we performed an unbiased proteomics screen using
mH2A as bait in an affinity purification. We expressed FLAG-
tagged mH2A in 293, a human fibroblast cell line, and carried
out FLAG immunoprecipitation followed by mass spectrometry
(IP-MS). We observed several known interactors of mH2A,
including PARP1 and linker histone H1 (Figure 1A, left and
middle, and Figure S1A available online) (Nusinow et al., 2007),
as well as MECP2 and HP1. In addition, IP-MS revealed the
280-kD ATRX protein (Figures 1A and S1B). We validated all in-
teracting proteins by western blot after FLAG-mH2A IP (Fig-
ure 1A, right, and data not shown).
ATRX caught our attention, as it was shown to be enriched on
the Xi by immunofluorescence (Baumann and De La Fuente,
2009) and has an ATPase and helicase domain (Clynes et al.,
2013; Ratnakumar and Bernstein, 2013; Ratnakumar et al.,
2012). ATRX is known as an unusual SNF2-like member of the
SWI/SNF family of chromatin remodelers, as it appears to have
only weak remodeling activity and does not affect nucleosome
phasing in vitro. It does, however, have ATPase activity that is
mildly stimulated by naked DNA and mononucleosomes (Tang
et al., 2004; Xue et al., 2003), and a translocase activity that dis-
places a third strand of a DNA triplex (Mitson et al., 2011; Xue
et al., 2003). The atypical N-terminal PHD finger domain of
ATRX (a.k.a., ATRX-Dnmt3-Dnmt3L [ADD] domain) binds to
unmodified histone H3-lysine 4 and to di- or tri-methylated H3-
lysine 9 (Dhayalan et al., 2011; Eustermann et al., 2011; Iwase
et al., 2011), in keepingwithATRX’s role inmaintaining pericentric
heterochromatin and telomeres (Goldberg et al., 2010; Lewis
et al., 2010).Mutations inATRXcauseX-linkedmental retardation
and alpha-thalassemia in humans, with80%ofmutationsmap-
ping to the PHD finger and helicase domains (Gibbons et al.,
2008). Although ATRX appears enriched on the Xi and plays a
role in peri-implantation development (Garrick et al., 2006),
whether ATRX plays a role in XCI is unknown.
To investigate, we generated clones of mouse embryonic
fibroblasts (MEF) with stable ATRX knockdown (KD) (shATRX-1,
2) and >90% depletion of ATRX protein (Figure 1B). We exam-
ined localization of EZH2, the PRC2 subunit that catalyzes theMiddle: western blot showing ATRX depletion but constant EZH2 levels in shATR
Right: Patterns of H3K27me3 observed. n = 100–150 per experiment.
(C) Left: Xist RNA FISH in indicated fibroblast lines with FITC acquisition times of
levels. Standard error (SE) bars from three independent experiments are shown
(D) Left: Immunostaining of ATRX and EZH2 in MEFs transiently transfected with
Right: H3K27me3 staining and Xist RNA FISH show no change in the intensity otrimethylation of histone H3 at lysine-27 (H3K27me3). Interest-
ingly, immunofluorescence showed that, while60%ofWT cells
showed prominent EZH2 foci on the Xi, only 16%–20% of ATRX
KD cells retained EZH2 (Figure 1B). Moreover, H3K27me3 on the
X chromosome was either absent or markedly reduced in
shATRX cells. At the same time, RNA fluorescent in situ hybridi-
zation (FISH) showed that Xist RNA localized poorly, with quanti-
tative RT-PCR showing that total Xist RNA levels were reduced
40%–60% (Figure 1C). Transient ATRX KDs in MEFs (48 hr)
showed that EZH2 localization was similarly compromised (Fig-
ure 1D). In transient knockdowns, there was no obvious distur-
bance to Xist localization or H3K27me3, consistent with the
short-term stability of Xist RNA and H3K27me3. Similar results
were obtained using two independent ATRX shRNAs, whereas
scrambled shRNA controls (Scr) resulted in no changes to Xist,
EZH2, or H3K27me3 localization. Xist levels and localization
were affected only in the long term, consistent with the notion
that H3K27me3 at the Xist promoter targeted by RepA facilitates
Xist upregulation (Sun et al., 2006; Zhao et al., 2008) and that
the H3K27me3 mark is depleted only after several rounds of
DNA replication. These findings hinted at a role of ATRX in
recruiting and spreading PRC2 to form a ‘‘cloud’’ on the Xi.
Xist-Mediated Recruitment of PRC2 Depends on ATRX
To examine whether there were sex-specific phenotypes of
ATRX deficiency, we used a mouse embryonic stem cell (ESC)
model to recapitulate random XCI during ex vivo cell differentia-
tion. We generated male and female ESC clones with stable
ATRX KD (Figures 2A and 2B; representative clones shown)
and compared their behavior to shScr control clones in time
course analyses from differentiation days 0–10. While no differ-
ences were evident from days 0–4, sex-specific differences
emerged between days 4–8 (Figures 2C and 2D). shATRX female
cells showed defective embryoid body (EB) outgrowth, whereas
shScr control andmale shATRXclones grew robustly (Figure 2C).
Immunostaining showed appropriate downregulation of pluripo-
tency markers, such as NANOG, between days 0–8 in all clones
(Figures S2A and S2B), indicating that the defect was not caused
by failed entry into the differentiation pathway per se. The Xist
regulator, Tsix, was also appropriately downregulated in shATRX
and shScr female ESC between days 0–10 (Figure 2D). These re-
sults indicated a developmental defect downstream of the differ-
entiation signal. In spite of normal Tsix downregulation, however,
Xist RNA was not appropriately upregulated in shATRX cells.
Furthermore, EZH2 targeting was severely compromised, as
only 9%of shATRX cells (n = 184) showed EZH2 enrichment (Fig-
ure 2E) and only 17% of cells showed H3K27me3 enrichment
(Figures 2F and 2G) on the Xi, even though H3K27me3 levels
were unperturbed globally (Figure 2G). Therefore, ATRX deple-
tion resulted in female-specific outgrowth defects related to an
inability to initiate XCI.X-1 and shATRTX-2 female MEFs.
500 ms and a gain of 61 for all samples. Right: qRT-PCR analyses of Xist RNA
with Student’s t test P values.
scrambled shRNA (shScr) and two shATRX constructs (shATRX-1, shATRX-2).
r foci number after transient ATRX KD.
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Figure 2. ATRX Is Required for Initiation of XCI during ES Cell Differentiation
(A) Western blot of ATRX and EZH2 after stable ATRX KD.
(B) ATRX immunostaining after stable ATRX-KD.
(legend continued on next page)
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To probe further, we circumvented a dependency of Xist
expression on ATRX and used an inducible transgenic system
in which Xist RNA is upregulated by addition of doxycycline
(dox) (Jeon and Lee, 2011). In this ‘‘X+P’’ system, Xist is carried
on an autosomal transgene in male cells and is upregulated >20-
fold upon induction, accompanied by recruitment of PRC2 along
the autosome in cis. In stable shATRX X+P clones (Figure 2H;
representative clone #4 shown), ATRX KD did not affect total
cellular EZH2 levels (Figure 2H) and dox-induction led to an
appropriate increase of Xist expression (Figure 2I), indicating
successful bypass of shATRX’s effect on Xist expression. Im-
muno-RNA FISH showed that EZH2 and H3K27me3 enrichment
were observed on the Xist-coated chromosome in 66%and 74%
of ATRX+ transgenic cells, respectively, confirming the suffi-
ciency of ectopic Xist expression to recruit and spread EZH2 in
cis (Figures 2J and 2K). However, on ATRX KD, EZH2 and
H3K27me3 recruitment decreased to 34% and 42%, respec-
tively. Thus, ATRX is required for Xist RNA-mediated recruitment
of PRC2.
ATRX Is a High-Affinity RNA-Binding Protein that Loads
PRC2 onto Xist RNA
To ask if Xist and ATRX directly interact in vivo, we performed
UV-crosslink RNA immunoprecipitation (UV-RIP; Figure 3A). As
expected, in ATRX+ transgenic system (X+P), EZH2 pulled
down Xist RNA under UV crosslinking conditions, consistent
with a direct interaction between EZH2 and Xist RNA (Zhao
et al., 2008). Intriguingly, ATRX also pulled down Xist RNA.
This association was detectable only when cells were subjected
to UV-crosslinking, suggesting that Xist is directly bound to
ATRX. Neither EZH2 nor ATRX pulled down the nonspecific
RNA control, U1 RNA. Significantly, when ATRX was knocked
down (X+P shATRX), the ability of EZH2 to interact with Xist
RNA was compromised (p = 0.02; Figure 3A). Similarly, EZH2-
Xist RNA interactions were disrupted in wild-type (WT) female
MEF cells when ATRX was depleted (p = 0.007; Figure 3B).
These data demonstrate that ATRX-Xist interaction facilitates
binding of PRC2 to Xist RNA in vivo.
To understand mechanism, we characterized ATRX-RNA in-
teractions in vitro. PRC2 binds RepA/Xist via Repeat A (Zhao
et al., 2008), a 435 nt motif consisting of 8.5 repeats of a
28-nucleotide sequence, with the potential to form several struc-
tures, including two long stem-loop structures, I-II and III-IV (Fig-
ure 3C)(Duszczyk et al., 2011; Maenner et al., 2010; Wutz et al.,
2002; Zhao et al., 2008). To ask how ATRX facilitates PRC2 inter-
action with Repeat A, we first performed RNA electromobility
shift assays (EMSA) using purified full-length ATRX (Figure 3D,
left, S3B). ATRX robustly shifted Repeat A in a concentration-(C) Representative phase contrast images of embryoid bodies during a different
(D) qRT-PCR analysis of Tsix and Xist RNA, normalized to tubulin RNA, during a
(E) Immunostaining of EZH2 and ATRX at day 8 of differentiation. (n) and % with
(F) Immunostaining of ATRX and H3K27me3 and Xist RNA FISH at day 10 of diff
(G) Left: western blot of indicated histone marks in day 8 ESCs. Graphs: Time cou
point.
(H) Western blot for ATRX, EZH2, and CTCF (control) in transgene (X+P) cells an
(I) qRT-PCR of Xist RNA before and after doxycycline induction in transgenic ce
(J,K) Immunostaining of ATRX, EZH2 (J), and H3K27me3 (K), and Xist RNA/DNA F
sample size (n) are indicated.dependent manner (Figure 3E), with 100% probe binding
at <100 nM ATRX protein (Figure S3C). To determine which re-
gion of Repeat A is sufficient for ATRX binding, we split Repeat
A into I-II versus III-IV (Figure S3A) and found that binding still
occurred, albeit at lower levels. We calculated dissociation con-
stants (Kd) from binding isotherms plotted from densitometric
analysis of double-filter binding assays (Figure S3D). Binding
curves were fitted using a nonlinear regression model, with
high R2 values showing excellent fit of data points to the curve
(Figure 3F). ATRX strongly bound Repeat A I-IV, with a Kd of
5.41 ± 0.40 nM. Subfragments I-II and III-IV retained binding
with Kd’s of 9.96 ± 0.89 nM and 17.90 ± 3.35 nM, respectively.
To test the specificity of ATRX-RNA interactions, we used the
first 300 nt of the Maltose Binding Protein (MBP) mRNA of
Escherichia coli and the P4-P6 ribozyme of Tetrahymena, two
noncognate RNAs. Neither bound ATRX to an appreciable extent
(Kd >>200 nM). We conclude that ATRX has high affinity and
specificity for Repeat A RNA.
Interestingly, ATRX could also bind Repeat A double-stranded
DNA (dsDNA; Kd = 15.7)(Figures 3G and 3H). However, it could
not bind well to the single-stranded DNA (ssDNA), nor MBP
and mouse Hotair dsDNAs (Figures 3G and 3H; Kd >>200 nM).
Therefore, ATRX has high affinity for both Repeat A RNA and
dsDNA, and belongs to an emerging class of ‘‘bivalent’’ chro-
matin factors capable of binding both RNA and DNA [e.g.,
CTCF (Sun et al., 2013) and YY1 (Jeon and Lee, 2011)]. Compe-
tition analysis showed that 10–1,0003 molar excess of cold
Repeat A dsDNA could not titrate away ATRX from Repeat A
I-IV RNA probe (Figure S3E) and, reciprocally, cold Repeat A
I-IV RNA could not titrate ATRX away from the dsDNA probe (Fig-
ure S3F), suggesting that ATRX interacts with RNA and dsDNA
via distinct domains. To delineate binding domains, we gener-
ated subfragments of ATRX (Figures 3D and 3I). The helicase
domain could bind Repeat A RNA at 10–25 nM, but not so well
as full-length ATRX. On the other hand, it bound dsDNA poorly,
if at all (Figure 3I). Gel shifts with the ADD domain showed bind-
ing to RNA at 100 nM, but not to DNA at the same concentration.
Because ATRX and PRC2 both bind Repeat A RNA, we asked
whether ATRX and PRC2 could make direct contact to create an
ATRX-RNA-PRC2 ternary complex. Using purified proteins, we
observed that they do (Figure 4A). This finding is consistent
with a yeast two-hybrid screen in which EZH2 was identified
as a directly interacting partner for ATRX (Cardoso et al.,
1998), but which has not been verified by in vivo analyses.
Notably, PRC2 components were not identified by our IP-MS
analysis, thoughATRXwas a clear interacting partner (Figure 1A).
This apparent discrepancy may be due to substoichiometric
ATRX-PRC2 associations in vivo and to mH2A being used as aiation time course.
differentiation time course. SE from three independent experiments shown.
EZH2 Xi foci are indicated.
erentiation. (n) and % positive are shown.
rse of Xist upregulation and acquisition of H3K27me3 foci. n = 80–120 per time
d in the same cell line expressing shATRX (X+P shATRX).
lls. SE from three independent experiments shown.
ISH in indicated cells lines after 24 hr dox induction. % with shown pattern and
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Figure 3. ATRX Binds RNA and Stimulates RNA Binding to PRC2
(A,B) RIP ±UV crosslinking in X+P transgenicMEFs after dox-induction for 24 hr (A) orWTMEF (B) Primers spanning Xist exons 1–3 andU1 snRNAswere used for
qPCR. One percent input was processed in parallel. SE from three independent experiments. P values calculated using Student’s t test.
(C) One possible structure of Repeat A (Maenner et al., 2010).
(D) Coomassie stain of purified full-length FLAG-ATRX-HA (left), C-terminal SNF2/helicase (middle), and N-terminal ADD (right) domains.
(E) RNA EMSA with ATRX at indicated concentrations and 0.2 nM of each probe. B, bound; U, unbound probe.
(F) Left: Binding Isotherms of ATRX for indicated RNAs. SE from three independent experiments shown. Right: table summarizing Kd’s and R
2 values. >>200 nM
indicates Kd’s out of the assay range. N/A, not applicable.
(G) EMSA of ATRX with different RNA, dsDNA, or ssDNA probes.
(H) Left: Binding Isotherms of ATRX for indicated DNAs. SE for three independent experiments shown for each point. Right: table summarizing Kd’s and R
2
values. >>200 nM indicates Kd’s out of the assay range. N/A, not applicable.
(I) RNA and DNA EMSAs using ATRX truncation mutants, with summary of results.bait in the proteomics screen. To confirm the ternary complex
in vitro, we performed tandem IP, first pulling down ATRX via
the HA tag, then immunoprecipitating PRC2 with an EZH2 anti-
body. Indeed, we observed end-labeled Repeat A RNA in the
tandem IP (Figure 4B), indicating that ATRX, PRC2, and Repeat
A RNA formed a ternary complex.
Given pairwise interactions between ATRX-RNA and ATRX-
DNA (Figures 3E–3I), we also explored the possibility of an874 Cell 159, 869–883, November 6, 2014 ª2014 Elsevier Inc.ATRX-RNA-DNA ternary complex. We immobilized biotinylated
Repeat A dsDNA on streptavidin beads and tested its ability to
bind the ATRX-Repeat A RNA complex. We reasoned that, if
the ATRX-RNA complex could engage dsDNA, RNA would be
visualized after elution from the column. Under these conditions,
RNA was minimally present, if at all, in the eluate (Figure 4C).
Thus, if an RNA:ATRX:dsDNA ternary complex could form, it
may be too transient to detect in vitro. We conclude that
A B
C
D
E
F
Figure 4. A Ternary Complex of ATRX,
PRC2, and RNA, with Stimulation of PRC2
Binding in an ATP-Dependent Manner
(A) FLAG-ATRX-HA binding to PRC2 ± ATP in the
absence of RNA. HA-immunoprecipitated material
was probed witha-EZH2 antibodies for western.
(B) Tandem IP to detect ternary complex formation
between ATRX, Repeat A RNA, and PRC2.
(C) Binding reaction to test for simultaneous as-
sociation of ATRX with RNA and DNA. RNA and
DNA can be discerned by their different electro-
phoretic mobilities.
(D) Top: Inverted image of RNA gel showing
Repeat A RNA recovered after EZH2 IP ± ATRX
and ± ATP. Bottom: western blot showing protein
levels in input and recovered after IP. Represen-
tative results from three independent experiments
shown.
(E) Photocrosslinking of PRC2 and Repeat A RNA
in the presence of ATRX with ATP or AMP-PNP.
Representative results from 5 biological replicates
shown.
(F) Filter binding of ATRX binding to Repeat A RNA
(left) or DNA (right) ± ATP and +AMP-PNP. ATRX
concentrations are indicated and SE from three
independent experiments shown. *p < 0.05.ATRX, PRC2, and Repeat A RNA forms a stable ternary complex,
but that ATRX likely does not form a stable ternary complex with
RNA and dsDNA in vitro.
With ATRX possessing an ATPase domain, we examined how
interaction dynamics might be changed by ATP. We assessed
PRC2-RNA binding in the presence or absence of ATRX and/or
ATP by immunoprecipitating EZH2 to quantitate the amount of
RNA bound (Figure 4D). Interestingly, ATRX’s stimulatory effect
was modestly increased (2-fold) in the presence of ATP, raising
the possibility that ATRX may act by remodeling Repeat A to a
configuration that promotes PRC2 binding. To test this idea,
we carried out an RNase protection assay with photocrosslink-
ing. We incubated PRC2 with thiolated radiolabeled Repeat A
RNA in the presence of ATRX and ATP or the nonhydrolysable
analog, AMP-PNP. The resulting complexes were subjected to
UV crosslinking and treated with RNase A, T1, and V1. In princi-
ple, protein-bound radiolabeled RNA would be protected from
digestion and detected in an SDS-PAGE autoradiograph. In
five biological replicates, the presence of ATRX and ATP consis-
tently resulted in greater protection of Repeat A RNA from
RNases, as visualized by the increased RNA signal bound to
EZH2/SUZ12 (Figure 4E), two known RNA-binding subunits of
PRC2 (Cifuentes-Rojas et al., 2014). Together, these experi-
ments show that ATRX stimulates binding of PRC2 to Repeat
A RNA in a manner that is enhanced by ATP.Cell 159, 869–883,Intriguingly, ATRX bound RNA and
DNA less well in the presence of ATP (Fig-
ure 4F). However, when AMP-PNP was
used, binding was not affected. This
observation suggests that the nucleic
acids are released by ATRX upon ATP hy-
drolysis. That is, ATRX may release RNA(and DNA) once the nucleic acid is reconfigured for PRC2 bind-
ing. The transient nature of the interactions may explain why a
dsDNA-ATRX-RNA ternary complex was difficult to detect (Fig-
ure 4C). The ATRX:RNA:PRC2 ternary complex may be easier
to detect (Figure 4B) because it is held in place by both PRC2-
RNA and PRC2-ATRX interactions. Combined, our data demon-
strate that ATRX directly promotes binding of PRC2 to RepA/Xist
RNA in vivo and in vitro.
A Hot Spot of ATRX Localization at the Xic
We investigated genomic binding patterns for ATRX by perform-
ing chromatin immunoprecipitation with deep sequencing (ChIP-
seq). To distinguish between Xa and Xi, we used genetically
marked hybrid cell lines in which the Xi is invariably ofMus mus-
culus (mus) origin and the Xa of Mus castaneus (cas) origin
(Ogawa et al., 2008; Pinter et al., 2012). Analysis of two biological
replicates revealed that, in MEFs and ESC, ATRX was broadly
distributed along all chromosomes (Chr)—including ChrX and a
representative autosome, Chr13—with preferential enrichment
in gene-dense regions (Figure 5A). Allele-specific analysis of
ChIP-seq coverage density plots for ATRX, EZH2, and
H3K27me3 (Pinter et al., 2012) and CHART-seq analysis of Xist
RNA (Simon et al., 2013) revealed that the four epitopes were
concentrated in the same regions of the Xi in female MEFs (Fig-
ure 5B), supporting the idea that ATRX, PRC2, and Xist RNA areNovember 6, 2014 ª2014 Elsevier Inc. 875
BD
en
si
ty
 (1
0-
kb
 b
in
s)
0 50 100 150  Mb
ChrX
0 40 80 120  Mb
Chr13
TSS Expressed
genes
ATRX
ESC day 0
ATRX
ESC day 7
ATRX
MEFs
A
D
4% 
24% 
72% 
TSS
Genic
Intergenic
MEF
4987
C
Xist +25 MB
ChrX
MEF
D
en
si
ty
 (5
0-
kb
 b
in
s)
-25 MB
10
15
M
EF
ESC day 0
-10
-15
-5
0
5
-10-15 -5 0 5 10 15
ATRX density
over genes
Xist
E
kb 100,600 100,610 100,620 100,630 100,640 100,650 100,660 100,670 100,680
cas
mus
comp
M
EF
 
cas
mus
comp
cas
mus
comp
ES
 d
ay
 7
ES
 d
ay
 0
Enriched Seg
Enriched Seg
Enriched Seg
G
[0 - 10]
[0 - 10]
[0 - 50]
[0 - 10]
[0 - 10]
[0 - 20]
[0 - 25]
[0 - 25]
[0 - 50]
Tsx Tsix
F H
mus 
(Xi)
cas
(Xa)
-2
0
-1
0
0
10
20
AT
R
X
 c
ov
er
ag
e
I
N
or
m
al
iz
ed
 fr
eq
ue
nc
y
Log2 coverage on mus alleles
(TSS + gene bodies)
0.
00
0.
10
0.
20
−10 −5 0 5
p=1
MEFChrX 
Chr13 
−10 −5 0 5
Log2 coverage on mus alleles
(TSS + gene bodies)
0.
00
0.
10
0.
20
0.
30
N
or
m
al
iz
ed
 fr
eq
ue
nc
y Expressed on Xa
Silent on Xa
p=0.8031
p=0.7506
0 50 100 150  Mb
D
en
si
ty
  (
10
-k
b 
bi
ns
)
Xist
ChrX MEF
ATRX
Xist RNA
EZH2
H3K27me3
ChrX
Xist
J
0.1 
0.3 
uRA uRF dRE Jarid1c 
%
 In
pu
t
*
*
**
0.1 
0.3 
uRA uRF dRE Jarid1c 
dRE
A F B C D E
uRAuRF
III.8
Xist-2lox
**
**
0.1 
0.3 
0.5 
uRA uRF dRE Jarid1c
III.8 
III.20 
uRA uRF dRE Jarid1c
0.1 
0.3 
0.5 
III.20
XaWTXi∆Xist
%
 In
pu
t
shATRX MEFᄛ
ATRX
IgG
WT MEFᄛ
ᄛ
Xist
ᄛ
WT
PRC2
ATRX
H3K27me3
Remodeled Repeat A
promotes PRC2 binding.
Xist becomes ATRX hotspot.
Spreading depends on
ATRX-RNA-PRC2 interactions.
Repeat A-disordered
Pol-II
Co-transcriptional
remodeling of Repeat A
by ATRX.
Xist 
RepA/Xist 
L
Repeat A-remodeled
TRE
CMV
X+P
X-RA
K
uRA uRF dRE
0.1 
0.2 
0.3 
0.4 
**
*
*
 X+P  X-RA  X+P  X+P X-RA  X-RA
 X+P  X-RA
 X
is
t
 T
g
%
 In
pu
t
 WT  WT  WT
ᄝ
dREuRA uRF
A F B C D E
ATRX
IgG
escapees
Pol-II
Pol-II
(legend on next page)
876 Cell 159, 869–883, November 6, 2014 ª2014 Elsevier Inc.
functionally linked. Strong ATRX binding occurred at 4,987
sites, with 4% in promoter regions (transcription start site
[TSS] ± 3 kb), 24% in coding gene bodies, and the rest in inter-
genic space (including enhancers, unannotated lncRNA tran-
scription units) (Figure 5C). This distribution is consistent with
previous ChIP-seq analysis in male ESCs (Law et al., 2010).
Among thousands of ATRX sites on ChrX, one locus stood out
(Figures 5D–5E, S4A, and S4B). Xist was among the top genic
hits in female MEFs (Figure 5F) and was covered by ATRX along
its entire length, contrasting with the restricted peaks character-
istic of other loci (Figure S4C). Allele-specific ChIP-seq of
shATRX MEFs showed loss of enriched signals at Xist (Fig-
ure S4D), confirming the specificity of the ATRX ChIP-seq
analysis. ATRX enrichment at Xistwas developmentally specific,
being absent in pre-XCI ESC and present in post-XCI MEF.
Furthermore, enrichment was observed only on the Xi (mus, Fig-
ure 5E). However, ATRX coverage across Xi alleles was not en-
riched relative to the genomic average (Figure 5G, representative
Chr13 shown; KS test, p = 1). Nor was ATRX coverage different
on average between two classes of Xi genes—those expressed
on Xa versus those that are silent (Figure 5H; KS test, p = 0.8031),
indicating that ATRX was no more enriched on X-genes that are
expressed in MEFs. Furthermore, ATRX coverage in genes that
escape XCI was not significantly different between Xa and Xi
(Figure 5I, purple dots; KS test, p = 0.75).
ChIP-qPCR confirmed that, in WT female MEFs, ATRX was
significantly enriched (relative to IgG pulldowns) within the Xist
gene regardless of what positions were queried (Figure 5J). By
contrast, Jarid1c—an X-linked gene that escapes XCI—did not
show significant ATRX enrichment. Enrichment at all Xist posi-
tions, including the nucleation center (uRF) was lost upon
ATRX KD (Figure 5J). ChIP-qPCR also verified the allele-specific
nature of ATRX localization. TheMEF line, XaWT Xi2lox (clone III.8),
carried two loxP sites flanking a 16 kb Xist sequence on the Xi,
whereas XaWT Xi DXist (clone III.20) carried a 16 kb conditional
deletion of Xist on the Xi (Zhang et al., 2007). ATRX was signifi-
cantly enriched at Xist only in the XaWT Xi2lox, the cell line bearingFigure 5. An ATRX Hot Spot at the Xist Locus Requires Function of Re
(A) Chromosome-wide profiles of ATRX coverage on Xi and Chr13 show input-no
transcriptionally active genes based on previous data (Yang et al., 2010).
(B) Allele-specific analysis: Normalized densities (10-kb bins, smoothened) of Xis
female MEFs along X.
(C) ATRX peak distribution in MEFs across promoter (TSS+/3 kb), genic, and in
(D) ATRX densities at 50-kb resolution across 50 Mb of the Xic, centered on Xist
(E) Allele-specific ATRX ChIP-seq tracks showingM. musculus (mus),M. castane
and MEFs. Comp track includes all aligned reads, both allelic and nonallelic. Pos
Representative autosomal tracks (Chr13) shown in Figure S4C.
(F) ATRX genic densities for all genes in MEFs (y axis) and ESC (x axis).
(G) ATRX coverages on gene bodies of mus alleles for ChrX and Chr13 in female
(H) Log2 ATRX coverage densities for Xi genes classified as ‘‘expressed on Xa’’
(I) ATRX coverage on XCI escapees (purple) on mus or cas alleles. Grey, all othe
KS test.
(J) Map of Xist alleles inWT, XaWT Xi2lox (III.8), and the conditional Xist deletion XaW
results (graphs) for ATRX. Averages of three independent ATRX ChIP expressed
(K) RNA/DNA FISH for Xist RNA and transgenic DNA in the transgenic X+P and X
Bottom graph: ChIP-pPCR of corresponding WT and transgenic MEF lines 24h a
ments shown with SE. *p < 0.05. **p < 0.005 (Student’s t test).
(L) Model: RepA/Xist RNAs cotranscriptionally recruit ATRX. ATRX may be ‘‘poise
enhances binding of PRC2. The Xist locus becomes an ATRX hot spot. Spreadinan intact Xist gene on the Xi (Figure 5J). Given that ATRX-RNA in-
teractions are mediated by Repeat A RNA (Figures 1, 2, 3, 4), we
asked whether the localization of ATRX to the chromatin hot spot
depended on Repeat A DNA. In the Xist transgene model, ChIP-
qPCR showed that, while deleting Repeat A (X-RA) did not affect
spreading of Xist RNA along the chromosome as shown by RNA
FISH (Figure 5K, top)(Jeon and Lee, 2011), it abolished ATRX
localization to the Xist locus (Figure 5K, bottom). Repeat A is
therefore essential for ATRX-Xist chromatin interactions in vivo.
We conclude that the Xi allele of Xist is a hot spot of ATRX
binding. These data lead to a model in which ATRX binds the
Repeat A motif and reconfigures the RepA/Xist transcript to pro-
mote PRC2 binding (Figure 5L), with poising of ATRX at the
Repeat A DNA potentially aiding ATRX-RNA interactions.
Following nucleation at the Xist hot spot, the ATRX-RNA-PRC2
ternary complex spreads outwardly along the Xi.
ATRX-Dependent Recruitment of PRC2 on a Global
Scale
We next investigated whether ATRX’s effect on PRC2 localiza-
tion extended beyond the Xi. We classified 21,677 annotated
unique RefSeq genes into equal quartiles (Q1–Q4) based on
ATRX coverage (Figure 6A; Tables S1 and S2), with Q1 having
high positive ATRX coverage and Q2 moderate coverage. Inter-
estingly, Q1 and Q2 harbored a large number of PRC2 target
genes, together accounting for 63% of all autosomal PRC2
target genes. By contrast, Q3 and Q4 had near-zero or negative
ATRX coverage and harbored fewer PRC2 target genes. To
determine whether loss of ATRX affected PRC2 recruitment to
genes marked by ATRX binding, we compared EZH2 and
H3K27me3 coverages in ATRX+ versus ATRX-deficient cells
(Figure 6B). Indeed, ATRX KD affected PRC2 localization and
function, with the 2- to 4-fold drop in EZH2 and H3K27me3 cov-
erages being highly significant (Figure 6B). Scatterplots showed
an obvious shift in EZH2 and H3K27me3 coverage for Q1 PRC2
targets (Figure 6C, purple dots; Table S1). We also examined
probability density functions for EZH2 and H3K27me3 topeat A
rmalized ATRX density over 10 Kb bins, gene (TSS) density, and the density of
t RNA, EZH2, H3K27me3 (Pinter et al., 2012; Simon et al., 2013), and ATRX in
tergenic regions.
.
us (cas), and composite (comp) reads across the Xist locus in day 0 and 7 ESC
itions of peaks/enriched segments (gray bars) are shown under comp tracks.
MEFs. KS test, p = 1.
(FPKMR 1) or ‘‘silent on Xa’’ (FPKM < 1). KS test, p = 0.80
r ChrX genes. P value was computed between mus and cas escapees using
T Xi DXist (III.20) MEF lines, with ChIP-qPCR amplicon positions and ChIP-qPCR
as % of input, with SE shown. *p < 0.05. **p < 0.005 (Student’s t test).
-RA male MEF lines after 24h dox-induction. Map of transgenes shown on top.
fter dox-induction of Xist. Averages of three independent ChIP-qPCR experi-
d’’ to bind RNA via Repeat A dsDNA. ATRX remodels Repeat A RNA motif and
g depends on the ATRX-RNA-PRC2 interactions.
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determine the likelihood that a given gene in ATRX-deficient cells
will have decreased EZH2 and H3K27me3 coverage based on
the population behavior of ATRX-PRC2 target genes (Figure 6D).
The distribution for ATRX KD is left and upwardly shifted, indi-
cating that the probability of a target gene in ATRX KD having
a low EZH2 (or H3K27me3) coverage is greater than that of the
same gene in ATRX+. To examine how EZH2 and H3K27me3
patterns change within gene bodies, we performed metagene
analysis (Figure 6E). In ATRX+, EZH2 and H3K27me3 patterns
showed characteristic gene-body enrichment. Upon ATRX KD,
EZH2 and H3K27me3 densities dramatically decreased in Q1
and Q2 genes, with decrease occurring at TSS’s and within
gene bodies. Minimal changes were observed for Q3 and Q4
genes (Figure 6E and data not shown). Analysis of biological rep-
licates showed good reproducibility (Figure S5, data not shown).
Collectively, these data demonstrate that ATRX is also required
to target PRC2 to autosomal genes.
Given the loss of PRC2 from genic regions upon ATRX KD,
we asked whether PRC2 became ectopically localized else-
where. Examination of global EZH2 and H3K27me3 ChIP-seq
patterns revealed an intriguing shift to intergenic space (Fig-
ure 6F). In ATRX+, EZH2 was bound to 3,178 sites, roughly
distributed equally among gene bodies, promoters, and inter-
genic space. On the other hand, in ATRX KD, EZH2 shifted
away from promoters and expanded into intergenic space.
Thus, ATRX is required to specify PRC2 localization to genes
in general.
Curiously, the distribution pattern for H3K27me3 peaks did not
change in ATRX-depleted cells, as the percentages occurring in
TSS, gene bodies, and intergenic space remained the same (Fig-
ure 6F, purple pie charts). At the same time, bulk H3K27me3
levels also did not change on ATRXKD inMEFs and ES cells (Fig-
ure 2G and data not shown). In spite of unchanged overall levels
of H3K27me3 and genomic ChIP-seq density, there was an
apparent loss of H3K27me3 peaks in many regions (Figure 6F).
Combined, these observations suggest a significant change in
H3K27me3 patterns concurrent with mistargeting of PRC2. At
the Polycomb target, Gpr26, loss of ATRX resulted in loss of
EZH2 binding to the promoter and a relative reduction in
H3K27me3 across the gene body (Figure 6G). At Tmem200a,
loss of EZH2 binding at the promoter was accompanied by a
new EZH2-binding site 70 kb upstream in intergenic space.
However, in spite of the newly acquired EZH2 site, H3K27me3
densities were not increased in the intergenic region. Altogether,
these data demonstrate that loss of ATRX function causesFigure 6. Global Roles of ATRX in Regulating PRC2 Localization and F
(A) RefSeq genes (21,677) divided into equal quartiles (Q1-Q4) based on ATRX co
each quartile are shown.
(B) Dot plots showing Log2 densities of EZH2 and H3K27me3 in ATRX+ versus AT
t test.
(C) Scatterplot of EZH2 andH3K27me3 densities in Log2 scale over all genes (gray
difference between ATRX+ and ATRX KD cells of Q1 PRC2 target genes is highl
(D) Probability density function for EZH2 and H3K27me3 based on coverages ov
(E) Metagene profiles of EZH2 (top) and H3K27me3 (bottom) coverage. The met
(F) Distribution of EZH2 and H3K27me3 peaks in indicated MEF samples. Peaks
called for each data set is indicated next to each chart.
(G) ChIP-seq tracks showing EZH2 and H3K27me3 densities in ATRX+ and ATR
RNA Seq (blue) tracks are as published (Yang et al., 2010; Yildirim et al., 2012).improper PRC2 targeting, shifting bulk PRC2 to ectopic inter-
genic space where chaotic or unstable PRC2 accumulation re-
sults in decreased selectivity of H3K27 methylation. We
conclude that ATRX is a specificity determinant for PRC2 local-
ization and function.
To determine whether failure of PRC2 targeting results in gene
expression changes, we tested specific Polycomb targets (Fig-
ures 7A, 7B, S6A, and S6B). Within the Hoxc and Hoxd clusters,
EZH2 and H3K27me3 were highly enriched in ATRX+ MEFs.
Upon ATRX KD, EZH2 and H3K27me3 levels were significantly
reduced, as evidenced by both decreased peak numbers as
well as overall coverages across the locus. Quantitative RT-
PCRanalysis revealed concomitant gene upregulation (Figure 7C
and S6C). At Parp12, Rnf19b, and Spock2, EZH2 bound the TSS
region in ATRX+ cells (Figure 7B). On ATRX KD, EZH2 and
H3K27me3 were consistently lost at the promoters (Figures 7B
and 7D; biological replicate shown in Figure S6D) and gene
expression increased 2- to 5-fold at all loci (Figure 7C). In
contrast, expression of Zc3h11a—a control that is not a
Polycomb target—did not change significantly after ATRX KD.
We conclude that ATRX plays a global role in gene regulation
by controlling PRC2 localization.
DISCUSSION
Although in vitro analysis shows that PRC2 is intrinsically
capable of distinguishing between cognate and nonspecific
transcripts (Cifuentes-Rojas et al., 2014), the thousands of
possible RNA partners in vivo (Zhao et al., 2010) argue that addi-
tional specificity determinants must exist in the physiological
context in order for PRC2 to be targeted in a locus-specific
manner. Our proteomics screen has identified ATRX as an
essential discrimination factor for PRC2 localization and function
on a global scale. During XCI, ATRX interacts with RepA/Xist
RNA and promotes loading of PRC2 (Figure 5L). ATRX is an
avid but also specific RNA-binding protein, with an impressive
Kd of 5 nM for Repeat A RNA. ATRX is also an avid DNA-bind-
ing protein (Kd 15 nM). ATRX’s interaction with Repeat A DNA
leaves it poised, enabling ATRX to bind RepA/Xist RNAs in a
cotranscriptional manner. Augmentation of ATRX’s effect on
Repeat A-PRC2 interactions by ATP suggests a role, potentially
as an RNA helicase, to remodel Repeat A RNA to a permissive
structure. This activity may parallel that of the MLE helicase for
the MSL-roX dosage compensation complex of the fruitfly (Ilik
et al., 2013; Maenner et al., 2013). In the case of XCI, absenceunction
verage. Average ATRX coverages and number of EZH2 target genes (peaks) in
RX KDMEFs for each quartile. ****p < < 0.0001, as calculated by the Student’s
dots) andQ1PRC2 target genes (purple dots) in ATRX+ or ATRXKDMEFs. The
y significant (p < 2.2 3 1016, Student’s t test) for both epitopes.
er the Q1-PRC2 target genes in the indicated MEF samples.
agenes are scaled 0 to 1 from genic start (TSS, x = 0) to end (TTS, x = 1).
are categorized as TSS (+/ 3Kb), genic, or intergenic. Total number of peaks
X-KD MEFs. Black bars, significantly enriched segments. H3K4me3 (pink) and
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of ATRX action at both Repeat A RNA and DNA precludes PRC2
targeting and spread along the Xi in cis.
ATRX’s specificity function extends beyond XCI. Without
ATRX, PRC2 cannot discriminate true targets from nonspecific
sequences. Loss of ATRX causes global shifts in PRC2 localiza-
tion and function, with PRC2 redistributing en masse to ectopic
sites in intergenic space and to noncanonical sites within coding
genes. At ectopic loci, PRC2 seems to lack proper context and
cofactors to carry out H3K27 methylation in a specific manner.
While fewer enriched H3K27me3 peaks are observed, overall
H3K27me3 levels are unchanged. Loss of ATRX-dependent
PRC2 function results in upregulation of Polycomb target genes
(Figures 7 and S6). We do not know whether ATRX action at
autosomal genes depends on noncoding transcripts, such as
RepA/Xist in the case of XCI. Because ATRX can bind DNA
directly (Figure 3H), ATRX-dependent targeting of PRC2 at auto-
somal loci may be mediated by either RNA or DNA (Figure 7E).
The large RNA interactome of PRC2 may also play a role. Finally
the presence of EZH2 peaks in Q3 andQ4 genes (Figure 6A) sug-
gests the presence of an ATRX-independent mechanism for
PRC2 recruitment as well: for example, at the Q4 Polycomb tar-
gets, Onecut1 and Klhl31, loss of ATRX did not affect EZH2 tar-
geting (Figure S7).
ATRX’s role in PRC2 targeting and function may help eluci-
date the pathogenesis of the X-linked alpha-thalassemia
mental retardation (ATR-X) syndrome (Gibbons et al., 2008), a
disease associated with aberrant chromatin at telomeres and
pericentric heterochromatin (Clynes et al., 2013). Mutations in
ATRX and its interacting partner, DAXX, are also frequently
mutated in tumors that rely on homologous recombination
instead of telomerase activation to circumvent telomere short-
ening. Our present study suggests that, in addition to abnor-
malities in constitutive heterochromatin caused by abnormal
H3K9 methylation, ATRX-associated diseases may also be
ascribed to dysregulated PRC2 function in facultative hetero-
chromatin. ATRX-mediated targeting of PRC2 thus provides a
new framework for understanding Polycomb biology and
human disease.
EXPERIMENTAL PROCEDURES
Cell Lines
Clonal Xist knockout MEFs, TsixTST/+ ESC, and X+P and X-RA male MEF lines
were described previously (Jeon and Lee, 2011; Ogawa et al., 2008; Zhang
et al., 2007). Mouse embryonic fibroblasts (MEFs) were immortalized
(SV40T) and selected for clonal cell lines with Xi of mus origin. The TsixTST allele
ensures exclusive inactivation of the mus X chromosome in ESC.
RNA FISH, DNA FISH and Immunostaining
RNA FISH, DNA FISH, or sequential RNA-DNA FISH and immunostaining were
described previously (Zhang et al., 2007).Figure 7. Loss of EZH2 from Target Genes as a Result of ATRX Knock
(A, B) Left panel: ChIP-seq tracks of theHoxd cluster (A) or individual genes (B) sho
statistically significant enriched segments. H3K4me3 (pink) and RNA Seq (blue)
(C) qRT-PCR analysis of expression levels before and after ATRX KD. Averages a
(D) EZH2 and H3K27me3 coverages over TSS before and after ATRX KD.
(E) Model: ATRX-dependent targeting of PRC2 on a genome-wide scale. ATRXm
those in the PRC2 interactome.Immunoprecipitation and Mass Spectrometry
Nuclear extract from 293F FLAG macroH2A cell lines was prepared and dia-
lyzed into BC100 buffer (20 mM Tris Cl pH 7.6, 2 mM EDTA, 100 mM KCl,
10% glycerol, and 0.2 mM PMSF), incubated with M2 agarose beads and
washed 3X with BC300. Flag peptide eluted complexes were run SDS-
PAGE gels and colloidal blue stained. MacroH2A IP specific bands were
sent for mass spectrometry. Proteins were digested and extracted peptides
(Wilker et al., 2007) loaded on a precolumn and separated by reverse phase
HPLC (Agilent) over a 75 min gradient before nanoelectrospray using Orbitrap
XLmass spectrometer (Thermo). Rawmass spectral data fileswere processed
as described (Johnson et al., 2012). Mascot peptide identifications were veri-
fied manually with the assistance of CAMV (Curran et al., 2013).
qRT-PCR, ChIP, and UV-RNA IP
RNA isolation and RT-PCR were performed according to manufacturer’s pro-
tocols (Invitrogen). ChIP and UV crosslinked RNA immunoprecipitation were
performed as described previously (Jeon and Lee, 2011). Primers and anti-
bodies are listed in Table S3.
Protein Expression and Purification
Full-length ATRX containing an N termFLAG tag andC termHA tagwas cloned
intoapfastbac vector (Invitrogen). Sf9 cellswere infectedwith virus for 60hr and
protein was purified using Flag M2 agarose. The helicase domain of ATRX with
an N term FLAG was cloned into the pdest10 vector (invitrogen). The ADD
domain of ATRX was cloned into pet101 vector and purified via a C term His
tag using Ni-NTA resin (QIAGEN) according to manufacturer’s instructions.
RNA and DNA EMSA and Double Filter Binding Assays
EMSAs and filter binding assays were performed as described previously
(Cifuentes-Rojas et al., 2014).
In Vitro Protein-RNA Interaction Assays
Twomicrograms ATRX, 2 mg PRC2, and 1 mg Repeat A RNAwere combined in
buffer containing 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1.5 mM MgCl2,
10 mg/ml BSA, 0.05% NP40, 1 mM DTT, 20U RNaseOUT (Invitrogen),
50 ng/ml yeast tRNA (Ambion Cat # AM7119), and 1 mMATP in a 20 ml reaction
and incubated at 37C for 30 min. Reactions were added to Protein G coupled
a-EZH2 at 4C for 2h and washed with 1X binding buffer. Beads were split in 2:
for RNA and protein analyses. RNA was eluted with formamide- urea buffer,
loaded on a 6% Urea-PAGE and SYBR Gold stained. Proteins were eluted
by boiling beads in SDS loading buffer.
For ternary complex IPs, 3mg ATRX, PRC2 and Repeat A RNA were incu-
bated at 30C in an RNA-EMSA-binding reaction (see above) and precipitated
using a-HA beads. Beads were washed with 1X binding buffer and complexes
eluted with 1 mg/ ml HA peptide. HA eluate was incubated with a-EZH2-protein
G dynabeads. After washing, beads were split into two parts: for RNA and pro-
tein western blot. RNA was eluted with 0.2 M glycine pH 2.0, neurtralized with
Tris.Cl pH 8.0 and end labeled in a PNK reaction for visualization.
Two hundred nanograms of 50 Biotin tagged Repeat A dsDNA was immobi-
lized to Streptavidin Myone dynabeads; 25 nM ATRX and 35 nM RNA were
combined in an EMSA reaction at 30C for 20 min, added to DNA and incu-
bated for 20 min at 30C. Beads were washed (as above) and nucleic acids
were end labeled and resolved on an 18% Urea-PAGE gel.
Photocrosslinking
In vitro transcription reactions were done as previously described (Hernandez
et al., 2008) for 16 hr at 37C with addition of 1 nM 4-Thio-UTP and 32Pa-GTPdown Results in Activation of These Genes
wing EZH2 andH3K27me3 patterns in ATRX+ and ATRX-KDMEFs. Black bars,
tracks were previously published (Yang et al., 2010; Yildirim et al., 2012).
nd SE of three independent experiments shown with Student’s t test P values.
ediates targeting either by directly binding DNA, or via regulatory RNAs such as
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and 32Pa-CTP at 0.6 mM. Binding reactions were performed as described pre-
viously (Cifuentes-Rojas et al., 2014), irradiated for 12 min with 365 nm UV and
digested with 0.1 ng RNase A, 1U RNase T1 and 1U RNase V1 for 20 min. SDS
loading buffer was added and samples run on a 3%–8% Tris-acetate SDS
gradient gel.
ChIP-Seq Read Mapping
ChIP-seq samples were sequenced using Illumina HiSeq2000 resulting 25–50
million 50 bp paired-end reads per sample. Using ASAP tool (http://www.
bioinformatics.babraham.ac.uk/projects/ASAP/), reads were aligned allele-
specifically to CAST/EiJ and 129S1/SvJm genomes constructed using high
quality polymorphisms to the C57/Bl6 reference genome (mm9). Twenty-five
percent of reads mapped uniquely and allele specifically and 45% equally
well to both genomes. Composite coverage tracks were generated using
alignment against mm9 with%2 alternative mappings allowed. Eighty percent
of reads were aligned, with 10%–15% of them discarded due to multiple alter-
nate mappings. Input-normalized read densities were computed using SPP
(Kharchenko et al., 2008) after PCR duplicate removal.
Peak Calling
RegionsofATRXenrichmentweredeterminedbasedon tagcounts ina1kbwin-
dow sliding with a 200 bp step. Statistical significance of enrichment of ChIP
versus input was estimated using negative binomial distribution, with mean
based on input tag count in input and size parameter (s) selected based on
manual inspection of resulting peak calls. Regions of enrichment were defined
by merging adjacent significantly enriched windows separated by%1 Kb.
Coverage over Genomic Elements
Coverageover TSS-proximal regions, genebodies, or nonoverlappinggenome-
wide 1Kb bins was calculated from input-normalized SPP read densities.
Actively expressed geneswere identified using the cutoff of FPKMR 1.0 based
on RNA-Seq data from (Yang et al., 2010). Input-normalized coverage over 1Kb
windows forXistCHARTandEZH2ChIP-seqwascomputedbasedondata from
(Pinter et al., 2012; Simon et al., 2013). Significance of change in EZH2 and
H3K27me3 densities produced by ATRX KDwas assessed by t test in separate
quartiles of unique RefSeq genes ranked by WT ATRX density over gene body.
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